Literature DB >> 22578747

Human β-defensin-3 alters, but does not inhibit, the binding of Porphyromonas gingivalis haemagglutinin B to the surface of human dendritic cells.

Jonathan R Van Hemert1, Erica N Recker, Deborah Dietrich, Ann Progulske-Fox, Zoya B Kurago, Katherine S Walters, Joseph E Cavanaugh, Kim A Brogden.   

Abstract

Human β-defensin-3 (HBD3) is a small, cationic, host defence peptide with broad antimicrobial activities and diverse innate immune functions. HBD3 binds to many microbial antigens and, in this study, we hypothesised that the known binding of HBD3 to Porphyromonas gingivalis recombinant haemagglutinin B (rHagB) alters, but does not inhibit, the binding of rHagB to human dendritic cells. To test this, human myeloid dendritic cells were incubated for 5 min with rHagB, HBD3 + rHagB (10:1 molar ratio), HBD3 or 0.1 M phosphate-buffered saline (PBS) (pH 7.2) and were then rapidly fixed and processed for confocal microscopy and ultramicrotomy. rHagB and HBD3 could be detected with primary monoclonal mouse antibody to rHagB (MoAb 1858) or polyclonal rabbit antibody to HBD3 (P241) and secondary fluorescent-labelled anti-mouse or anti-rabbit antibodies (confocal microscopy) or protein A-colloidal gold (immunoelectron microscopy). In cells incubated with rHagB only, fluorescence and protein A-colloidal gold were seen at the cell surface and throughout the cytoplasm. In cells incubated with HBD3+rHagB, fluorescence was observed only at the cell surface in a 'string of pearls' configuration. Overall, these results suggest that HBD3 binding to rHagB alters, but does not inhibit, the binding of rHagB to human myeloid dendritic cells.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22578747      PMCID: PMC3371132          DOI: 10.1016/j.ijantimicag.2012.03.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  14 in total

1.  Expression of human beta-defensin-3 in gingival epithelia.

Authors:  Qian Lu; Lakshman P Samaranayake; Richard P Darveau; Lijian Jin
Journal:  J Periodontal Res       Date:  2005-12       Impact factor: 4.419

2.  Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement.

Authors:  George Hajishengallis; Shuang Liang; Mark A Payne; Ahmed Hashim; Ravi Jotwani; Mehmet A Eskan; Megan L McIntosh; Asil Alsam; Keith L Kirkwood; John D Lambris; Richard P Darveau; Michael A Curtis
Journal:  Cell Host Microbe       Date:  2011-10-27       Impact factor: 21.023

3.  Correlation between beta-defensin expression and induction profiles in gingival keratinocytes.

Authors:  Sophie Joly; Connie C Organ; Georgia K Johnson; Paul B McCray; Janet M Guthmiller
Journal:  Mol Immunol       Date:  2004-12-15       Impact factor: 4.407

4.  The novel human beta-defensin-3 is widely expressed in oral tissues.

Authors:  Anton Dunsche; Yahya Açil; Henrik Dommisch; Reiner Siebert; Jens M Schröder; Søren Jepsen
Journal:  Eur J Oral Sci       Date:  2002-04       Impact factor: 2.612

5.  Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic.

Authors:  J Harder; J Bartels; E Christophers; J M Schroder
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

6.  Hemagglutinin B is involved in the adherence of Porphyromonas gingivalis to human coronary artery endothelial cells.

Authors:  Hong Song; Myriam Bélanger; Joan Whitlock; Emil Kozarov; Ann Progulske-Fox
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

7.  Antimicrobial anionic peptide binds in vivo to Mannheimia (Pasteurella) haemolytica attached to ovine alveolar epithelium.

Authors:  Mohammad Heidari; Amir Hamir; Randall C Cutlip; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2002-07       Impact factor: 5.283

8.  Human alpha- and beta-defensins bind to immobilized adhesins from Porphyromonas gingivalis.

Authors:  Deborah E Dietrich; Xiangjun Xiao; Deborah V Dawson; Myriam Bélanger; Hua Xie; Ann Progulske-Fox; Kim A Brogden
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

9.  Human β-defensin 3 affects the activity of pro-inflammatory pathways associated with MyD88 and TRIF.

Authors:  Fiona Semple; Heather MacPherson; Sheila Webb; Sarah L Cox; Lucy J Mallin; Christine Tyrrell; Graeme R Grimes; Colin A Semple; Matthew A Nix; Glenn L Millhauser; Julia R Dorin
Journal:  Eur J Immunol       Date:  2011-09-06       Impact factor: 5.532

10.  Oral antimicrobial peptides and biological control of caries.

Authors:  Beverly A Dale; Renchuan Tao; Janet R Kimball; Richard J Jurevic
Journal:  BMC Oral Health       Date:  2006-06-15       Impact factor: 2.757

View more
  3 in total

1.  Cytotoxicity of HBD3 for dendritic cells, normal human epidermal keratinocytes, hTERT keratinocytes, and primary oral gingival epithelial keratinocytes in cell culture conditions.

Authors:  Nattawut Leelakanok; Carol L Fischer; Amber M Bates; Janet M Guthmiller; Georgia K Johnson; Aliasger K Salem; Kim A Brogden; Nicole K Brogden
Journal:  Toxicol Lett       Date:  2015-09-11       Impact factor: 4.372

2.  Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus.

Authors:  Lauren E Harvey; Karl G Kohlgraf; Leslie A Mehalick; Monica Raina; Erica N Recker; Saumya Radhakrishnan; Samiksha Avinash Prasad; Robinson Vidva; Ann Progulske-Fox; Joseph E Cavanaugh; Shireen Vali; Kim A Brogden
Journal:  Sci Rep       Date:  2013-02-06       Impact factor: 4.379

3.  Histatin 5 binds to Porphyromonas gingivalis hemagglutinin B (HagB) and alters HagB-induced chemokine responses.

Authors:  Derek S Borgwardt; Aaron D Martin; Jonathan R Van Hemert; Jianyi Yang; Carol L Fischer; Erica N Recker; Prashant R Nair; Robinson Vidva; Shwetha Chandrashekaraiah; Ann Progulske-Fox; David Drake; Joseph E Cavanaugh; Shireen Vali; Yang Zhang; Kim A Brogden
Journal:  Sci Rep       Date:  2014-01-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.